- Home
- BRTX vs BTTC Comparison
BRTX vs BTTC Comparison
Compare BRTX & BTTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRTX
- BTTC
- Stock Information
- Founded
- BRTX 1997
- BTTC 1990
- Country
- BRTX United States
- BTTC Malaysia
- Employees
- BRTX N/A
- BTTC N/A
- Industry
- BRTX Managed Health Care
- BTTC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BRTX Health Care
- BTTC Health Care
- Exchange
- BRTX Nasdaq
- BTTC Nasdaq
- Market Cap
- BRTX 12.5M
- BTTC 12.3M
- IPO Year
- BRTX N/A
- BTTC N/A
- Fundamental
- Price
- BRTX $1.66
- BTTC $8.00
- Analyst Decision
- BRTX
- BTTC
- Analyst Count
- BRTX 0
- BTTC 0
- Target Price
- BRTX N/A
- BTTC N/A
- AVG Volume (30 Days)
- BRTX 74.0K
- BTTC 1.8M
- Earning Date
- BRTX 11-11-2025
- BTTC 01-01-0001
- Dividend Yield
- BRTX N/A
- BTTC N/A
- EPS Growth
- BRTX N/A
- BTTC N/A
- EPS
- BRTX N/A
- BTTC N/A
- Revenue
- BRTX $605,200.00
- BTTC N/A
- Revenue This Year
- BRTX $232.67
- BTTC N/A
- Revenue Next Year
- BRTX $52.92
- BTTC N/A
- P/E Ratio
- BRTX N/A
- BTTC N/A
- Revenue Growth
- BRTX 247.62
- BTTC N/A
- 52 Week Low
- BRTX $1.19
- BTTC $5.48
- 52 Week High
- BRTX $2.55
- BTTC $39.00
- Technical
- Relative Strength Index (RSI)
- BRTX 65.28
- BTTC N/A
- Support Level
- BRTX $1.19
- BTTC N/A
- Resistance Level
- BRTX $1.47
- BTTC N/A
- Average True Range (ATR)
- BRTX 0.09
- BTTC 0.00
- MACD
- BRTX 0.02
- BTTC 0.00
- Stochastic Oscillator
- BRTX 100.00
- BTTC 0.00
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.